ArticleMolecular and clinical oncology2017
Value of neutrophil-to-lymphocyte ratio for predicting lung cancer prognosis: A meta-analysis of 7,219 patients.
Article in Molecular and clinical oncology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 62 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
62 citing papers in PubMed, 4 syntheses or guidelines pooled it.
- Neutrophil to lymphocyte ratio and cancer prognosis: an umbrella review of systematic reviews and meta-analyses of observational studies.BMC medicine · 2020Pooled it
- Pooled it
- The prognostic values of neutrophil to lymphocyte ratio for outcomes in chronic obstructive pulmonary disease.Medicine · 2019Pooled it
- Defining the role of neutrophil-to-lymphocyte ratio in COPD: a systematic literature review.International journal of chronic obstructive pulmonary diseasePooled it
- Methylation-derived Neutrophil-to-Lymphocyte Ratio and Lung Cancer Risk in Heavy Smokers.Cancer prevention research (Philadelphia, Pa.) · 2018Trial
- Baseline neutrophil-to-lymphocyte ratio predicts survival time after the initiation of nintedanib in patients with interstitial lung disease.BMC pulmonary medicine · 2026Article
- Pretreatment and dynamic neutrophil-to-lymphocyte ratio in relation to CT-based volumetric response to platinum-based neoadjuvant chemotherapy in NSCLC.Biomolecules & biomedicine · 2026Article
- Towards Personalised Screening for Lung Cancer: A Sex-Stratified Approach in a Danish Cohort Integrating Pre-Diagnostic Systemic Inflammatory Indexes with Smoking Status and Age.Respiration; international review of thoracic diseases · 2026Article
- Prognostic value of preoperative inflammatory markers in resectable non-small cell lung cancer: a multi-center retrospective study based on logistic regression and machine learning techniques.Frontiers in medicine · 2026Article
- Role of Systemic Inflammatory Markers in the Differential Diagnosis of Organizing Pneumonia and Lung Cancer.APMIS : acta pathologica, microbiologica, et immunologica Scandinavica · 2025Article
- The Correlation Between NLR, RDW, and Pulmonary Hypertension in Patients With Bronchiectasis and Chronic Obstructive Pulmonary Disease Overlap Syndrome.The clinical respiratory journal · 2025Article
- Article
- Higher PHQ-9 score levels and neutrophil-to-lymphocyte ratio are associated with increased risks of stroke, all-cause mortality, and MACE in NHANES 2005-2018.BMC psychiatry · 2025Article
- Targeting neutrophils for cancer therapy.Nature reviews. Drug discovery · 2025Review
- First-line immune checkpoint inhibitors plus chemotherapy in Taiwanese patients with extensive-stage small-cell lung cancer.Journal of the Chinese Medical Association : JCMA · 2025Article
- Baseline and changes in inflammatory parameters for patients with EGFR-mutated NSCLC treated with afatinib.Thoracic cancer · 2025Article
- Role of Blood Cell Indexes in Progresses to ESRD.Indian journal of clinical biochemistry : IJCB · 2025Article
- Clinical Significance of the Peripheral Blood Neutrophil-to-Lymphocyte Ratio in Predicting Chemotherapy Outcomes for Small Cell Lung Cancer.Cancer management and research · 2025Article
- Clinical significance of postoperative thrombocytosis after vats lobectomy for NSCLC.Journal of cardiothoracic surgery · 2024Article
- The Multifaceted Role of Neutrophils in NSCLC in the Era of Immune Checkpoint Inhibitors.Cancers · 2024Review
2 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Current evidence suggests that the neutrophil-to-lymphocyte ratio (NLR) may be a biomarker for poor prognosis in lung cancer, although this association remains controversial. Therefore, a meta-analysis was performed to evaluate the association between NLR and lung cancer outcome. A systematic literature search was performed through the PubMed, Embase and Cochrane Library databases (until July 30, 2016), to identify studies evaluating the association between NLR and overall survival (OS) and/or progression-free survival (PFS) among patients with lung cancer. Based on the results of this search, data from 18 studies involving 7,219 patients with lung cancer were evaluated. The pooled hazard ratio (HR) suggested that elevated pretreatment NLR predicted poor OS [HR=1.46, 95% confidence interval (CI): 1.30-1.64] and poor PFS (HR=1.42, 95% CI: 1.15-1.75) among patients with lung cancer. Subgroup analysis revealed that the prognostic value of NLR for predicting poor OS increased among patients who underwent surgery (HR=1.50, 95% CI: 1.21-1.84) or patients with early-stage disease (HR=1.64, 95% CI: 1.37-1.97). An NLR cut-off value of ≥4 significantly predicted poor OS (HR=1.56, 95% CI: 1.31-1.85) and PFS (HR=1.54, 95% CI: 1.13-1.82), particularly in the cases of small-cell lung cancer. Thus, the results of the present meta-analysis suggested that an elevated pretreatment NLR (e.g., ≥4) may be considered as a biomarker for poor prognosis in patients with lung cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.